Open Access

Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma

  • Authors:
    • Chunping Wang
    • Yinying Lu
    • Hong Wang
    • Xudong Gao
    • Wenlin Bai
    • Jianhui Qu
    • Guilin Xu
    • Zhenzhen Zhang
    • Zhen Zeng
    • Lin Zhou
    • Linjing An
    • Jiyun Lv
    • Yongping Yang
  • View Affiliations

  • Published online on: May 10, 2012     https://doi.org/10.3892/etm.2012.569
  • Pages: 188-196
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sorafenib may prolong survival in patients with advanced hepatocellular carcinoma (HCC), but with limited efficacy. The present study aimed to prospectively investigate the efficacy and analyze the prognostic factors for survival in sorafenib-treated patients with advanced HCC. The baseline characteristics and clinical outcomes of 110 patients with advanced hepatitis B virus-related HCC treated with sorafenib with/without local therapy (transarterial chemoembolization with/without cryoablation) at a single liver cancer center were recorded. Predictors of progression-free survival (PFS) and overall survival (OS) were determined by multivariate analysis. A total of 14 (12.7%) patients achieved complete response (CR), 16 (14.5%) achieved partial response (PR) and 40 (36.4%) achieved stable disease (SD) lasting longer than 8 weeks. The median OS and PFS for the whole cohort were 10.5 [95% confidence interval (CI), 8.7-12.3] and 5.0 months (95% CI, 3.7-6.3), respectively. Sorafenib in combination with local therapy was an independent predictor for longer PFS, whereas Eastern Cooperative Group (ECOG) performance status (PS) and Child-Pugh class were associated with reduced PFS. Local therapy was associated with longer OS while ECOG PS and α-fetoprotein were associated with reduced OS. In a subset of patients with radiological progressive disease, a significant difference was found in OS between patients who continued taking sorafenib and those who discontinued therapy (11 vs. 7.5 months, P<0.001). In conclusion, sorafenib in combination with local therapy (transarterial chemoembolization with/without cryoablation) was independently associated with longer OS and PFS in advanced HCC patients. Poor ECOG PS was associated with shorter OS and PFS and is thus a marker of poor outcomes in sorafenib-treated HCC patients.
View Figures
View References

Related Articles

Journal Cover

August 2012
Volume 4 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, Zhou L, et al: Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 4: 188-196, 2012
APA
Wang, C., Lu, Y., Wang, H., Gao, X., Bai, W., Qu, J. ... Yang, Y. (2012). Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Experimental and Therapeutic Medicine, 4, 188-196. https://doi.org/10.3892/etm.2012.569
MLA
Wang, C., Lu, Y., Wang, H., Gao, X., Bai, W., Qu, J., Xu, G., Zhang, Z., Zeng, Z., Zhou, L., An, L., Lv, J., Yang, Y."Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma". Experimental and Therapeutic Medicine 4.2 (2012): 188-196.
Chicago
Wang, C., Lu, Y., Wang, H., Gao, X., Bai, W., Qu, J., Xu, G., Zhang, Z., Zeng, Z., Zhou, L., An, L., Lv, J., Yang, Y."Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma". Experimental and Therapeutic Medicine 4, no. 2 (2012): 188-196. https://doi.org/10.3892/etm.2012.569